Recent executive appointments 8-K filings

Mikkel Pitzner, age 58, appointed to Board effective July 16, 2026. Compensation: $4,500 quarterly in common stock.

Irina Krasik appointed to Board of Directors effective July 22, 2026. Ms. Krasik brings M&A, investing, corporate strategy and governance experience from Stellex Capital Management and prior roles.

John M. Holmes, Chairman and CEO, granted 161,500 shares of performance-based restricted stock with $15M target value, vesting July 31, 2031, subject to stock price hurdles of $175–$250.

Company entered into amended and restated employment agreements with CEO Gary Atkinson and CFO/General Counsel Alex Andre on July 22, 2026, harmonizing change of control benefits and IRC compliance provisions.

Adam B. Sefchick's compensation increased as CFO and approved for role as Interim CEO since June 15, 2026. Salary raised to $302,000, bonus target to $70,000, restricted stock grant of 20,222 shares, and $10,000 monthly interim CEO stipend

Neil Barua appointed as independent director effective July 24, 2026, with term expiring at 2027 Annual Meeting. Appointed to Compensation Committee and Technology & Innovation Committee.

Celso L. Goncalves Jr. appointed President and Chief Financial Officer effective July 21, 2026. Base salary increased to $1,000,000; severance multiple increased from 2 to 3 years. Also appointed to Board.

E. Morgan Flatley appointed to the Human Resources Committee following the July 22, 2026 Annual Meeting. Stockholders also approved amendment and restatement of Long-Term Stock Incentive Plan effective July 22, 2026.

Compensation Committee approved special performance-based RSU grants to Ronald F. Clarke (300,000 PSUs) and Armando L. Netto (28,213 PSUs) effective July 22, 2026, with vesting tied to stock price hurdles through August 31, 2028.

Board adopted Amended and Restated Executive Severance Plan updating severance for executive officers, effective July 23, 2026, aligning with market practice.

Board approved Executive Severance Plan governing future executive officer separations and special cash bonuses for ~1,100 managing directors and above, including CEO and CFO.

Ty R. Taylor declined to stand for re-election to the Board of Directors at the 2026 election. He continues serving until his term expires December 31, 2026.

Board appointed Kewei Huang as Co-Chief Executive Officer effective July 22, 2026, to serve alongside existing CEO Sheng-Yih Chang.

David I. Goulden appointed as director and committee member effective July 24, 2026. Former CFO at Booking Holdings. Will receive pro-rata director compensation.

Michael H. Carrel appointed to Board of Directors effective July 20, 2026, as Class III director with committee assignments. Non-departure event.

Thomas E. Waldron appointed as director, effective immediately. Board size increased from six to seven. Term expires at 2027 annual meeting. Quarterly dividend of $0.53 per share declared.

Compensation Committee approved special one-time equity awards (50% PSUs, 50% RSUs) to Kenneth Sharp (CFO), Kenneth Bedingfield, and Samir Mehta, with target values of $5M, $10M, and $10M respectively, vesting in 2029.

Board approved PSU grants to CEO Harold Bevis (250k), COO Tim French (140k), and CFO Chris Bohnert (110k) on July 23, 2026, vesting based on performance goals through 2028.

Board approved restricted stock unit award of 125,298 shares to CEO Lou Torchio effective July 31, 2026, with four-year vesting contingent on continued employment.

Compensation Committee approved stock option grants and conditional cash bonuses to CEO Robert C. Jahr and CFO Lawrence A. Kenyon, contingent on FDA approval of ONS-5010 by July 31, 2026.